Top Gainers Ahead of Market -- Research on Genco Shipping & Trading, Progenics Pharma, Rambus, and Exact Sciences

LONDON, March 19, 2014 /PRNewswire/ --

The US markets saw a positive sentiment on Tuesday, March 18, 2014, as the NASDAQ Composite closed at 4,333.31, up 1.25%, the Dow Jones Industrial Average ended the session at 16,336.19, up 0.55% and the S&P 500 edged 0.72% higher to finish the trading session at 1,872.25. During the session, gains in the Information Technology, Health Care, and Energy sectors positively impacted the broader market. A number of stocks saw large movements, including Genco Shipping & Trading Ltd (NYSE: GNK), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Rambus Inc. (NASDAQ: RMBS), and Exact Sciences Corp. (NASDAQ: EXAS). Free technical research on GNK, PGNX, RMBS, and EXAS can be downloaded upon signing up at:

http://www.investor-edge.com/325-register

Shares in Genco Shipping & Trading Ltd closed Tuesday's session at $1.58, up 8.22%, with a trading volume of 1.90 million shares as compared to a three months average volume of 1.69 million shares. The stock oscillated between $1.43 and $1.59 during the trading session. Shares of Genco Shipping & Trading Ltd have advanced 7.48% in the previous three trading sessions, while the same has fallen by 12.22% in the last one month and 36.80% on YTD basis. The S&P 500 Industrials Sector Index mapped a gain of 0.50% during the trading session and charted up 1.45% in the last one month. Moreover, the stock is trading at the RSI of 34.90 and below its 50-day and 200-day moving averages of $1.98 and $2.38, respectively. Sign up today to read free research on GNK at:

http://www.investor-edge.com/325-GNK-19Mar2014.pdf

On Tuesday, shares in Progenics Pharmaceuticals Inc. ended the session at $4.74, up 9.42% from the previous day's closing price of $4.33. A total of 2.23 million shares were traded as compared to a three months average volume of 1.46 million shares. The stock traded between $4.29 and $4.88 during the trading session. Shares in Progenics Pharmaceuticals Inc. have gained 8.67% in the previous three trading sessions and 0.59% in the last three months, while the same has lost 11.11% on YTD basis. The S&P 500 Health Care Sector Index mapped a gain of 1.17% during the trading session and charted up 1.47% in the last one month. Furthermore, the stock is trading at the RSI of 39.01 and below its 50-day and 200-day moving averages of $5.28 and $4.95, respectively. Sign up today to read free research on PGNX at:

http://www.investor-edge.com/325-PGNX-19Mar2014.pdf

Rambus Inc.'s stock finished Tuesday's session at $10.56, recording a gain of 6.56%. A total of 2.26 million shares were traded which is above the three months average volume of 0.98 million shares. The stock fluctuated between $9.85 and $10.80 during the session. Rambus Inc.'s shares have surged 7.87% in the previous three trading sessions, 13.30% in the last one month and 11.51% on YTD basis. The S&P 500 Information Technology Sector Index mapped a gain of 1.35% during the trading session and charted up 1.13% in the last one month. Additionally, the stock is trading at the RSI of 64.16 and above its 50-day and 200-day moving averages of $9.14 and $9.03, respectively. Sign up today to read free research on RMBS at:

http://www.investor-edge.com/325-RMBS-19Mar2014.pdf

Exact Sciences Corp.'s stock gained 9.82% on Tuesday, closing the session at $14.42. A total of 1.79 million shares were traded as compared to a three months average volume of 0.96 million shares. The stock vacillated between $13.17 and $14.45 during the session. Exact Sciences Corp.'s shares have rallied 13.72% in the last one month, 20.07% in the previous three months and 22.72% on YTD basis. The S&P 500 Health Care Sector Index advanced 1.17% during the trading session and charted up 8.57% in the previous three months. Furthermore, the stock is trading at the RSI of 45.49 and above its 50-day and 200-day moving averages of $13.45 and $12.54, respectively. Sign up today to read free research on EXAS at:

http://www.investor-edge.com/325-EXAS-19Mar2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED